China's healthcare regulator on Sunday defended the efficacy of off-patent medicines it had approved to be distributed through the country's public hospitals, saying an investigation into quality concerns had found them to be unsubstantiated.

In an interview with the state-backed People's Daily newspaper, the National Healthcare Security Administration said it performed evaluations to ensure that so-called generic drugs were consistent with the quality and efficacy of original research drugs and strictly supervised them after approval.

The NHSA launched an investigation last month after local media cited doctors in Beijing and Shanghai as saying that the cheaper generic drugs used at public hospitals did not appear to have the same efficacy or side effects as those made by Western pharmaceutical companies.

The regulator said it had looked into those claims by speaking to relevant experts as well as the heads of seven hospitals and found that perceptions that generic drugs such as anaesthetics and laxatives were less effective arose from "subjective feelings".

3 Ways Robots Affect the Economy

3 Ways Robots Affect the Economy

Understanding Wealth: How Is It Defined and Measured?

Understanding Wealth: How Is It Defined and Measured?

How Importing and Exporting Impacts the Economy

How Importing and Exporting Impacts the Economy

President Biden's Plan for Combating COVID-19

President Biden's Plan for Combating COVID-19

Completed property mortgages trending up

Completed property mortgages trending up

CK Asset to offer 2,700 homes at five projects

CK Asset to offer 2,700 homes at five projects

RedNote takes up Times Square office

RedNote takes up Times Square office

City's retailers face further downturn in 2025, warns bank

City's retailers face further downturn in 2025, warns bank

Tariff exemption on Chinese goods under US$800 scrapped

Tariff exemption on Chinese goods under US$800 scrapped

Ditch investment visa home curbs, urges Midland boss

Ditch investment visa home curbs, urges Midland boss

AI, tech firms bolster HK, mainland stocks

AI, tech firms bolster HK, mainland stocks

Xiaomi softly debunks rumors of AI glasses' early launch

Xiaomi softly debunks rumors of AI glasses' early launch